Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

British Journal of Cancer

Volumn 105, Issue 5, 2011, Pages 628-639

  Harrington, K J ^a   Billingham, L J ^b   Brunner, T B ^c   Burnet, N G ^d   Chan, C S ^e   Hoskin, P ^f   MacKay, R I ^g   Maughan, T S ^h   MacDougall, J ^e   McKenna, W G ^c   Nutting, C M ^a   Oliver, A ^e   Plummer, R ⁱ   Stratford, I J ^j   Illidge, T ^j  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

assessment; clinical; early; novel radiosensitisers; preclinical

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; BIOLOGICAL MARKER; CISPLATIN; COBALT CHLORIDE; CYTOTOXIC AGENT; DEFEROXAMINE; FLUOROURACIL; GEMCITABINE; LAPATINIB; PLATINUM DERIVATIVE; RADIOSENSITIZING AGENT; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ADD ON THERAPY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL LINE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HYPOXIA; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPH NODE METASTASIS; METASTASIS; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIATION DOSE; RADIOSENSITIZATION; SKIN METASTASIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VALIDATION PROCESS;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIATION-SENSITIZING AGENTS;

EID: 80052023514     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.240     Document Type: Article

References (90)

1. Adkins DR, DiPersio JF (2008) Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 15: 555-560
2. Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ (2006) The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 18: 747-760 (Pubitemid 44645413)
3. Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, Einhorn L, Ball D, Trovo MG, Groen HJ, Bonner JA, Le Chevalier T, Arriagada R (2006) Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17: 473-483 (Pubitemid 43329586)
4. Bashir FA, Parry JM, Windsor PM (2008) Use of a modified hemi-body irradiation technique for metastatic carcinoma of the prostate: report of a 10-year experience. Clin Oncol (R Coll Radiol) 20: 591-598
5. Baumann M, DuBois W, Pu A, Freeman J, Suit HD (1992) Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. Int J Radiat Oncol Biol Phys 23: 803-809
6. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, MacDonald TJ, Holland EC (2010) Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 70: 2548-2557
7. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37: 4078-4101
8. Bentzen SM, Harari PM, Bernier J (2007) Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4: 172-180 (Pubitemid 46358854)
9. Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25: 4096-4103 (Pubitemid 47492954)
10. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (# 22931) and RTOG (# 9501). Head Neck 27: 843-850 (Pubitemid 41395696)
11. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945-1952 (Pubitemid 38580197)
12. Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 68: 654-661 (Pubitemid 46818766)
13. Bhide SA, Nutting CM (2010) Recent advances in radiotherapy. BMC Med 8: 25
14. Bliss CI (1956) The calculation of microbial assays. Bacteriol Rev 20: 243-258
15. Cabrera CM, Cobo F, Nieto A, Cortés JL, Montes RM, Catalina P, Concha A (2006) Identity tests: determination of cell line cross-contamination. Cytotechnology 51: 45-50 (Pubitemid 44763385)
16. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942 (Pubitemid 17027905)
17. Chang C, Biedermann KA, Mezzina M, Brown JM (1993) Characterization of the DNA double strand break repair defect in SCID mice. Cancer Res 53: 1244-1248 (Pubitemid 23097096)
18. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
19. Clarkson R, Lindsay PE, Ansell S, Wilson G, Jelveh S, Hill RP, Jaffray DA (2011) Characterization of image quality and image-guidance performance of a preclinical microirradiator. Med Phys 38: 845-856
20. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944
21. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212
22. Costelloe CM, Chuang HH, Madewell JE, Ueno NT (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1: 80-92
23. Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, Temam S, Cupissol D, De Raucourt D, Maroudias N, Nutting CM, Compton N, Midwinter D, Downie L, Biswas-Baldwin N, El-Hariry I, Harrington KJ (2011) Effects of lapatinib monotherapy on apoptosis and proliferation: results of a randomized phase II study in therapy-näve patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer (in press)
24. Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti LM, Lawrence TS, Zalupski MM (2007) Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol 25: 4587-4592 (Pubitemid 350035317)
25. Dörr W, Spekl K, Martin M (2002) Radiation-induced oral mucositis in mice: strain differences. Cell Prolif 35(Suppl 1): 60-67 (Pubitemid 34985148)
26. Eglen RM, Reisine T (2009) The current status of drug discovery against the human kinome. Assay Drug Dev Technol 7: 22-43
27. Epperly MW, Lai SY, Kanai AJ, Mason N, Lopresi B, Dixon T, Franicola D, Niu Y, Wilson WR, Greenberger JS (2010) Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy. In Vivo 24: 1-8
28. Eriksson D, Stigbrand T (2010) Radiation-induced cell death mechanisms. Tumour Biol 31: 363-372
29. Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10: 718-726
30. Garrett MD, Walton MI, McDonald E, Judson I, Workman P (2003) The contemporary drug development process: advances and challenges in preclinical and clinical development. Prog Cell Cycle Res 5: 145-158
31. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358: 781-786 (Pubitemid 32868726)
32. Gridley DS, Baer JR, Cao JD, Miller GM, Kim DW, Timiryasova TM, Fodor I, Slater JM (2002) TNF-alpha gene and proton radiotherapy in an orthotopic brain tumor model. Int J Oncol 21: 251-259
33. Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A'Hern R, Miles EA, McNair H, Bidmead M, Warrington AP, Dearnaley DP, Harrington KJ, Nutting CM (2007a) A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 85: 36-41 (Pubitemid 47570062)
34. Hagemann RF, Sigdestad CP, Lesher S (1971a) Intestinal crypt survival and total and per crypt levels of proliferative cellularity following irradiation: single X-ray exposures. Radiat Res 46: 533-546
35. Hagemann RF, Sigdestad CP, Lesher S (1971b) Intestinal crypt survival and total and per crypt levels of proliferative cellularity following irradiation: fractionated X-ray exposures. Radiat Res 47: 149-158
36. Hall EJ, Astor M, Biaglow J, Parham JC (1982) The enhanced sensitivity of mammalian cells to killing by X rays after prolonged exposure to several nitroimidazoles. Int J Radiat Oncol Biol Phys 8: 447-451 (Pubitemid 12090555)
37. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70 (Pubitemid 30046295)
38. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K (2001) Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114(Part 24): 4557-4565 (Pubitemid 34086890)
39. Harrington K, Jankowska P, Hingorani M (2007) Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol (R Coll Radiol) 19: 561-571 (Pubitemid 47308644)
40. Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D'Ambrosio C, Turner SJ, Pandeshwara JS, Bourhis J (2009) Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1100-1107
41. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204 (Pubitemid 351301852)
42. Hornsey S, Vatistas S (1963) Some characteristics of the survival curve of crypt cells of the small intestine of the mouse deduced after whole body X irradiation. Br J Radiol 36: 795-800
43. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62 (Pubitemid 40093472)
44. Judson I (2010) Targeted therapies in soft tissue sarcomas. Ann Oncol 21(Suppl 7): vii277-vii280
45. Lally BE, Geiger GA, Kridel S, Arcury-Quandt AE, Robbins ME, Kock ND, Wheeler K, Peddi P, Georgakilas A, Kao GD, Koumenis C (2007) Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res 67: 8791-8799 (Pubitemid 47437455)
46. Lee CJ, Spalding AC, Ben-Josef E, Wang L, Simeone DM (2010) In vivo bioluminescent imaging of irradiated orthotopic pancreatic cancer xenografts in nonobese diabetic-severe combined immunodeficient mice: a novel method for targeting and assaying efficacy of ionizing radiation. Transl Oncol 3: 153-159
47. Lester JF, Macbeth FR, Toy E, Coles B (2006) Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev, (4): CD002143
48. Lordick F, Siewert JR (2005) Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 8: 78-85 (Pubitemid 40655516)
49. LoRusso PM, Boerner SA, Seymour L (2010) An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 16: 1710-1718
50. Lutz S, Hoskin P, Chow E (2009) Update on palliative radiotherapy endpoints for bone metastasis trials. Clin Oncol (R Coll Radiol) 21: 659-661
51. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26: 3582-3589
52. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL, Debenham PG (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012-8017 (Pubitemid 32642678)
53. Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS (2010) Radiotherapy research priorities for the UK. Clin Oncol (R Coll Radiol) 22: 707-709
54. Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS (2010) Recent advances in combined modality therapy. Oncologist 15: 372-381
55. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J (2010) Mechanism of radiosensitisation by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70: 4972-4981
56. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259
57. Niyazi M, Belka C (2006) Isobologram analysis of triple therapies. Radiat Oncol 1: 39
58. Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6: 10-21 (Pubitemid 26029371)
59. Padhani AR, Koh DM (2011) Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 19: 181-209
60. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949-955 (Pubitemid 30148259)
61. Politi K, Pao W (2011) How genetically engineered mouse tumour models provide insights into human cancers. J Clin Oncol 29(16): 2273-2281
62. Pollard JM, Gatti RA (2009) Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 74: 1323-1331
63. Potter DM (2002) Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Stat Med 21: 1805-1823 (Pubitemid 34732642)
64. Price DA, Blagg J, Jones L, Greene N, Wager T (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol 5: 921-931
65. Rakhorst HA, Tra WM, Posthumus-Van Sluijs ST, Hovius SE, Levendag PC, Kanaar R, Hofer SO (2006) Quantitative analysis of radiation-induced DNA break repair in a cultured oral mucosal model. Tissue Eng 12: 3395-3403 (Pubitemid 46037163)
66. Rao RD, Brown PD, Buckner JC (2007) Innovation in the management of brain metastases. Oncology (Williston Park) 21: 473-481 (Pubitemid 46641442)
67. Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, Tabb B, Lawrence S, Kinders RJ, Bonner WM, Sedelnikova OA (2011) g-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol 682: 249-270
68. Rygaard J, Povlsen CO (1969) Heterotransplantation of a human malignant tumour to 'Nude' mice. Acta Pathol Microbiol Scand 77: 758-760
69. Saha D, Watkins L, Yin Y, Thorpe P, Story MD, Song K, Raghavan P, Timmerman R, Chen B, Minna JD, Solberg TD (2010) An orthotopic lung tumor model for image-guided microirradiation in rats. Radiat Res 174: 62-71
70. Sak A, Stuschke M (2010) Use of gH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 20: 223-231
71. Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21: 1457-1465 (Pubitemid 37522705)
72. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 82: 1107-1112 (Pubitemid 20213250)
73. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073 (Pubitemid 44453332)
74. Staffurth J, Radiotherapy Development Board (2010) A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 22: 643-657
75. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91 (Pubitemid 9120186)
76. Stone HB, Withers HR (1975) Metronidazole: effect on radiosensitivity of tumor and normal tissues in mice. J Natl Cancer Inst 55: 1189-1194
77. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466
78. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 15: 406-420
79. Thoms J, Bristow RG (2010) DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20: 217-222
80. Tiscornia G, Singer O, Ikawa M, Verma IM (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 100: 1844-1848 (Pubitemid 36254536)
81. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19: 940-945 (Pubitemid 32947572)
82. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ (2008) Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 14: 912-923 (Pubitemid 351231176)
83. UKCCCR guidelines for the use of cell lines in cancer research (2000). Br J Cancer 82: 1495-1509
84. Urbano TG, Clark CH, Hansen VN, Adams EJ, Miles EA, Mc Nair H, Bidmead AM, Warrington J, Dearnaley DP, Harmer C, Harrington KJ, Nutting CM (2007b) Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol 85: 58-63 (Pubitemid 47562585)
85. Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185: 538-543 (Pubitemid 36627845)
86. Verheij M, Vens C, van Triest B (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 13: 29-43
87. Workman P (2003a) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol 52(Suppl 1): S45-S56 (Pubitemid 37047024)
88. Workman P (2003b) How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9: 891-902 (Pubitemid 36367612)
89. Yap TA, Sandhu SK, Workman P, de Bono JS (2010) Envisioning the future of early anticancer drug development. Nat Rev Cancer 10: 514-523
90. Zaidi SH, Huddart RA, Harrington KJ (2009) Novel targeted radio-sensitisers in cancer treatment. Curr Drug Discov Technol 6: 103-134